新しいアトピ-性疾患治療剤,N-(3′,4′-dimethoxycinnamoyl)anthranilic acid(N-5′)の薬理学的性質-4-抗炎症作用について

概要

論文の詳細を見る
The present experiment was an attempt to determine the anti-inflammatory activity of N-5'. The authors have already reported that when given orally, N-5' shows a dose-dependent, significant inhibition on the homologous passive cutaneous anaphylaxis (PCA) in rats mainly through an inhibition of histamine release from mast cells, nevertheless, the drug at a dose sufficient to inhibit the homologous PCA, shows only slight inhibition on the paw edema induced by carrageenin. In the present experiment, the inhibitory effect of N-5' on rat paw edema induced by carrageenin, dextran or egg white was only slight at a dose level of 200 mg/ kg or less which is sufficient to inhibit homologous PCA, but significant at 400 mg/kg of the drug. The potency of 400 mg/kg of N-5' was nearly equal to that of 200 mg/kg of phenylbutazone. N-5' at a dose of only 400 mg/kg showed a significant inhibition on the increased vascular permeability induced by histamine, hyaluronidase or acetic acid. The inhibitory effect was more potent than that of 200 mg/kg of phenylbutazone. The inhibitory effect of 400 mg/kg N-5' on the granuloma tissue formation was equipotent to that of 100 mg/kg of phenylbutazone. It was speculated from our findings that the moderate anti-inflammatory activity of N-5' should contribute to clinical application of the drug for allergic diseases which involve complications of inflammation.